CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

CRISPR Therapeutics AG ( NASDAQ: CRSP) TD Cowen 45th Annual Healthcare Conference March 3, 2025 10:30 AM ET ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...

CRISPR Therapeutics (NASDAQ:CRSP – Free Report) had its target price decreased by Citigroup from $89.00 to $82.00 in a report ...

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has received a consensus rating of “Moderate Buy” from the twenty-two ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

When Vijay Sankaran was an MD-PhD student at Harvard Medical School in the mid-2000s, one of his first clinical encounters ...

We recently published a list of the 10 Oversold Pharma Stocks to Buy According to Analysts. In this article, we are going to ...

CRISPR Therapeutics (CRSP) stock slips after a strong rally driven by earnings beats and analyst upgrades. Explore future catalysts and investment insights.

Fintel reports that on February 14, 2025, Evercore ISI Group upgraded their outlook for CRISPR Therapeutics (NasdaqGM:CRSP) from In-Line to Outperform. Analyst Price Forecast Suggests 90.46% Upside As ...